RT Journal Article SR Electronic T1 Thoracic cancer patients and Covid-19: experience from a portuguese tertiary care unit JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA3850 DO 10.1183/13993003.congress-2021.PA3850 VO 58 IS suppl 65 A1 Raquel Viana A1 Daniel Coutinho A1 Eloísa Silva A1 Sérgio Campainha A1 Margarida Dias A1 Telma Costa A1 Ana Barroso YR 2021 UL http://erj.ersjournals.com/content/58/suppl_65/PA3850.abstract AB -Cancer patients have higher risk of Covid-19 infection and may develop severe disease with increased mortality. Thoracic CancERs International CoVid-19 COLlaboraTion Registry (Teravolt) is a global consortium that assesses outcomes in this group of patients.-Describe TERAVOLT results in a portuguese tertiary care hospital.-Descriptive study. Patients diagnosed with COVID-19 at Centro Hospitalar Vila Nova de Gaia Thoracic Tumors Unit between march 2020 and january 2021 were included. Demographic, clinical, pathological and radiological data were collected.-31 patients: 71% males, mean age 65,2. 74,2% had non small cell lung carcinoma. Most patients had ECOG PS 1. Disease stage was diverse (IV-63%; III-18,5%; II-3,7%; I-14,8%). 77,4% presented comorbidities. 59,1% were not receiving treatment at time of COVID-19 diagnosis. Fatigue and dyspnea were the most common symptoms; 29% were asymptomatic. 41,9% were hospitalized, none was admitted to the intensive care unit. Pneumonia was the most frequent complication. Death rate was 16,1%.-Compared to TERAVOLT published results, there is a lower death rate in our population (16,1% vs. 32%). All deaths occurred in stage IV patients with ECOG PS 2-3, who were diagnosed with COVID-19 during hospitalization. The percentage of asymptomatic patients may be explained by mandatory SARS-CoV-2 PCR screening tests performed before treatments and invasive procedures. Telephonic visits, less frequent immunotherapy dosing schedules and tyrosine kinase inhibitors given for a 2-month period were implemented measures to prevent unnecessary hospital visits. Protocols regarding infection control measures and treatment options in this group of patients should be created.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3850.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).